← Back to Clinical Trials
Recruiting NCT06854549

NCT06854549 Impact of Picture Book Reading on Preterm Infant Stability, Parental Anxiety, and Parent-Child Attachment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06854549
Status Recruiting
Phase
Sponsor National Yang Ming Chiao Tung University
Condition Effects of Parent-Child Reading on Preterm Infant Stability, Parental Anxiety, and Parent-Child Attachment
Study Type INTERVENTIONAL
Enrollment 88 participants
Start Date 2025-06-23
Primary Completion 2026-06-28

Eligibility & Interventions

Sex All sexes
Min Age 28 Weeks
Max Age 37 Weeks
Study Type INTERVENTIONAL
Interventions
Parental Reading Picture-book

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 88 participants in total. It began in 2025-06-23 with a primary completion date of 2026-06-28.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study investigates the effects of a parent-child picture book reading intervention on the cardiopulmonary stability of preterm infants, parental anxiety, and parent-child attachment. A randomized controlled trial will be conducted in a neonatal intensive care unit (NICU) and neonatal intermediate care unit in northern Taiwan. A total of 88 preterm infants and their parents will be randomly assigned to an intervention or control group. Parents in the intervention group will read picture books to their infants from a corrected gestational age of 28 weeks to 36 weeks and 6 days. Physiological data (heart rate, respiratory rate, oxygen saturation, and heart rate variability) and parental anxiety levels will be assessed at multiple time points. The study aims to determine whether this intervention improves infant stability, reduces parental anxiety, and enhances parent-child attachment, contributing to improved neonatal care practices.

Eligibility Criteria

Inclusion Criteria: * Preterm Infants: 1. Born between 28+0 and 36+6 weeks of gestation. 2. Transferred out of the incubator as per medical advice. 3. Passed the newborn hearing screening in both ears. * Parents of Preterm Infants: 1. Able to read and comprehend Chinese-language materials. 2. Capable of communicating in Mandarin. Exclusion Criteria: * Preterm Infants: 1. Presence of external ear abnormalities. 2. Receiving sedatives, hypnotics, or caffeine therapy. * Parents of Preterm Infants: 1. Having auditory or speech impairments.

Contact & Investigator

Central Contact

CHI-WEN CHEN, PhD

✉ chiwenchen@nycu.edu.tw

📞 +886989581661

Principal Investigator

Mei-Jy Jeng, PhD

STUDY CHAIR

Taipei Veterans General Hospital, Taipei

Frequently Asked Questions

Who can join the NCT06854549 clinical trial?

This trial is open to participants of all sexes, aged 28 Weeks or older, up to 37 Weeks, studying Effects of Parent-Child Reading on Preterm Infant Stability, Parental Anxiety, and Parent-Child Attachment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06854549 currently recruiting?

Yes, NCT06854549 is actively recruiting participants. Contact the research team at chiwenchen@nycu.edu.tw for enrollment information.

Where is the NCT06854549 trial being conducted?

This trial is being conducted at Taipei, Taiwan.

Who is sponsoring the NCT06854549 clinical trial?

NCT06854549 is sponsored by National Yang Ming Chiao Tung University. The principal investigator is Mei-Jy Jeng, PhD at Taipei Veterans General Hospital, Taipei. The trial plans to enroll 88 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology